<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">37670937</article-id>
      <article-id pub-id-type="pmc">10475715</article-id>
      <article-id pub-id-type="publisher-id">423878</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S423878</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Quantitative Network Comparisons of REM Sleep Without Atonia Across the α-Synucleinopathy Spectrum: A Systematic Review</article-title>
        <alt-title alt-title-type="running-authors">Byun et al</alt-title>
        <alt-title alt-title-type="running-title">Byun et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Byun</surname>
            <given-names>Jung-Ick</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Tae-Won</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
          <xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref>
          <xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8834-0568</contrib-id>
          <name>
            <surname>Sunwoo</surname>
            <given-names>Jun-Sang</given-names>
          </name>
          <xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shin</surname>
            <given-names>Won Chul</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="aff0006" ref-type="aff">
<sup>6</sup>
</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Kwon</surname>
            <given-names>Oh-Young</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
          <xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref>
          <xref rid="aff0007" ref-type="aff">
<sup>7</sup>
</xref>
          <xref rid="ft0001" ref-type="author-notes">*</xref>
          <xref rid="an0001" ref-type="corresp"/>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Jung</surname>
            <given-names>Ki-Young</given-names>
          </name>
          <xref rid="aff0008" ref-type="aff">
<sup>8</sup>
</xref>
          <xref rid="ft0001" ref-type="author-notes">*</xref>
          <xref rid="an0002" ref-type="corresp"/>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0002"><label>2</label><institution>Department of Neurology, Gyeongsang National University College of Medicine</institution>, <addr-line>Jinju</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0003"><label>3</label><institution>Department of Neurology, Gyeongsang National University Changwon Hospital</institution>, <addr-line>Changwon</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0004"><label>4</label><institution>Institute of Science, Gyeongsang National University College of Medicine</institution>, <addr-line>Jinju</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0005"><label>5</label><institution>Department of Neurology, Kangbuk Samsung Hospital</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0006"><label>6</label><institution>Department of Medicine, AgeTech-service Convergence Major, Kyung Hee University</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0007"><label>7</label><institution>Department of Neurology, Gyeongsang National University Hospital</institution>, <addr-line>Jinju</addr-line>, <country>Republic of Korea</country></aff>
        <aff id="aff0008"><label>8</label><institution>Department of Neurology, Seoul National University Hospital</institution>, <addr-line>Seoul</addr-line>, <country>Republic of Korea</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Oh-Young Kwon, <institution>Department of Neurology, Gyeongsang National University College of Medicine</institution>, <addr-line>15, Jinjudae-ro 816beon-gil</addr-line>, <addr-line>Jinju</addr-line>, <addr-line>52727</addr-line>, <country>Republic of Korea</country>, <phone>Tel +82-55-750-8288</phone>, Email oykwon@gnu.ac.kr</corresp>
        <corresp id="an0002">Ki-Young Jung, <institution>Department of Neurology, Seoul National University Hospital, Neuroscience Research Institute, Seoul National University College of Medicine</institution>, <addr-line>101 Daehak-Ro, Jongno-Gu</addr-line>, <addr-line>Seoul</addr-line>, <addr-line>110-744</addr-line>, <country>Republic of Korea</country>, <phone>Tel +82-2-920-6649</phone>, Email jungky@snu.ac.kr</corresp>
        <fn id="ft0001">
          <label>*</label>
          <p><citation_analysis attribute="neither">These authors contributed equally to this work</citation_analysis></p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>8</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <volume>15</volume>
      <fpage>691</fpage>
      <lpage>703</lpage>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>6</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2023 Byun et al.</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>Byun et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Purpose</title>
          <p><citation_analysis attribute="neither">Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by REM sleep without atonia (RWA) and is regarded as the prodromal stage of α-synucleinopathies, such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). RWA is also associated with neurodegeneration driven by α-synucleinopathy. However, the level of RWA across the α-synucleinopathy spectrum remains elusive. We aimed to rate the percentage of RWA across the α-synucleinopathy spectrum, encompassing prodromal and overt phenotypes.</citation_analysis></p>
        </sec>
        <sec>
          <title>Methods</title>
          <p><citation_analysis attribute="positive">A systematic search was conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases. We included cohort, cross-sectional, and case–control studies comparing the RWA percentage during REM sleep evaluated by tonic chin activity (RWA%-T) or by phasic chin activity (RWA%-P) across the α-synucleinopathy spectrum. Bayesian network meta-analysis was used to combine both direct and indirect evidence regarding the group differences in the RWA%-T and RWA%-P. The surface under the cumulative ranking curve was used to estimate the ranked probability.</citation_analysis></p>
        </sec>
        <sec>
          <title>Results</title>
          <p><citation_analysis attribute="positive">Fifteen articles met the inclusion criteria. The investigations included 204 iRBD, 295 PD with RBD (PDwtRBD), 187 PD without RBD (PDwoRBD), 42 MSAwtRBD, 9 DLBwtRBD patients, and 246 controls. MSAwtRBD ranked first in RWA%-T, whereas iRBD ranked first in RWA%-P. RWA% in PDwoRBD patients was comparable to that in the controls and was lower than that in PDwtRBD patients.</citation_analysis></p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p><citation_analysis attribute="neither">Overt phenotypes such as MSAwtRBD and PDwtRBD ranked high in RWA%-T, whereas iRBD, a prodromal type, ranked highest in RWA%-P. Taken together, our data suggest that the percentage of neurodegeneration in RBD patients may be associated with RWA%-T rather than RWA%-P.</citation_analysis></p>
        </sec>
        <sec>
          <title>Prospero Registration Number</title>
          <p><citation_analysis attribute="neither">CRD42021276445.</citation_analysis></p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>REM sleep behavior disorder</kwd>
        <kwd>α-synucleinopathy</kwd>
        <kwd>REM sleep without atonia</kwd>
        <kwd>network meta-analysis</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>the National Research Foundation of Korea (NRF)</institution></institution-wrap>
</funding-source>
        </award-group>
        <funding-statement>This work was supported by the National Research Foundation of Korea (NRF) (No. NRF-2020R1C1C1013160, 2022R1H1A2092329). This work was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (2017R1A2B2012280), the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &amp; Future Planning (2017M3C7A1029688).</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="3"/>
        <table-count count="4"/>
        <ref-count count="58"/>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by REM sleep without atonia (RWA) and dream enactment behavior (DEB) without any neurological disorders. According to Braak staging for Parkinson’s disease (PD), REM sleep behavior disorder (RBD) is associated with α-synuclein deposits in the medulla and pontine tegmentum before the involvement of the substantia nigra.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, iRBD is known as a prodromal α-synucleinopathy that can precede the motor symptoms of PD.</citation_analysis></p>
      <p><citation_analysis attribute="neither">More than 70% of iRBD patients will eventually phenoconvert to overt α-synucleinopathy phenotypes within 10–15 years after diagnosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2–5</xref></citation_analysis><citation_analysis attribute="neither"> The overt α-synucleinopathy phenotypes include PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> They share common clinical features but may represent different degrees of progression of α-synuclein pathology.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, RBD is a common symptom of these neurodegenerative disorders; the prevalence of RBD in MSA is 80 to 100%, 50 to 80% in DLB and 16 to 47% in PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">RWA is characterized by excessive tonic and/or phasic electromyography (EMG) activities during REM sleep recorded by polysomnography (PSG).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> Although criteria for amplitude and duration of muscle activity differ among the methods, they have been used to rate the percentage of RWA. In iRBD, the percentage of RWA (RWA%) during REM sleep increased over time,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither"> and RWA increments predicted future conversion to neurodegenerative disorder.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12–14</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, the severity or duration of PD was linked to the quantity of RWA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither"> Therefore, the percentage of RWA during REM sleep is accepted as a neurophysiological marker of neurodegeneration, especially in α-synucleinopathies.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="positive"> However, there is a lack of integrated and systematic evidence to provide information regarding the relative difference in the RWA percentage during REM sleep among the prodromal and overt α-synucleinopathy phenotypes. Only a few studies have directly compared the percentage of REM atonia loss between two or more groups.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Network meta-analysis (NMA) aims to synthesize all available direct and indirect evidence across studies</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither"> so that the RWA can be compared within various experimental groups, including prodromal and overt α-synucleinopathies and control groups. Furthermore, the NMA allows groups to be ranked according to their probabilities of being the best or worst for a given outcome.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0018" ref-type="bibr">18</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">In this systematic review, we adopted the NMA approach to compare group differences by combining direct and indirect evidence within a network of reported studies. To date, most studies evaluating RWA have used at least the chin muscle. Therefore, we included currently available studies evaluating RWA using either tonic or phasic muscle activities for the NMA. Information from the other studies using limb or combined muscle activities was not sufficient for the NMA. Comparison of the “RWA percentage during REM sleep evaluated by tonic chin activity” (RWA%-T) or that by phasic chin activity (RWA%-P) among the α-synucleinopathy phenotypes could be valuable to evaluate the significance of RWA according to the neurodegenerative process. The comparison may reveal different pathomechanisms among the phenotypes and confirm the diagnostic value of RWA quantification in differentiating one from another.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Materials and Methods</title>
      <p><citation_analysis attribute="positive">This study was performed in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020) guidelines.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> The protocol of this study was specified in advance and was registered in PROSPERO (International Prospective Register of Systematic Reviews) with the registration number CRD42021277446.</citation_analysis></p>
      <sec id="s0002-s2001">
        <title>Eligibility Criteria</title>
        <sec id="s0002-s2001-s3001">
          <title>Inclusion Criteria</title>
          <p><citation_analysis attribute="positive">We included studies that provided information on the manual scoring of RWA%-T or RWA%-P values in two or more study groups, including prodromal or overt α-synucleinopathy phenotypes and controls. The target study groups of primary studies for this review were patients with iRBD, PD with RBD (PDwtRBD), PD without RBD (PDwoRBD), MSA with RBD (MSAwtRBD), DLB with RBD (DLBwtRBD) and controls without RBD or neurodegenerative disorders. We considered prospective and retrospective cohort, cross-sectional and case–control studies as the subject studies of this review. This review also includes longitudinal studies with baseline evaluations that were adequate for this meta-analysis. Using approximation methods, the median and interquartile range were converted to the estimated mean and standard deviation.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis></p>
        </sec>
        <sec id="s0002-s2001-s3002">
          <title>Exclusion Criteria</title>
          <p><citation_analysis attribute="neither">We excluded duplicates or subcohorts of already published cohorts and studies investigating animals or pediatric populations. Studies that did not specify comorbid RBD in overt α-synucleinopathy or that did not specify comorbid overt α-synucleinopathy in RBD patients were excluded from the analysis. We did not exclude studies based on publication date or language.</citation_analysis></p>
        </sec>
      </sec>
      <sec id="s0002-s2002">
        <title>Search Strategy</title>
        <p><citation_analysis attribute="positive">We established a search strategy after selecting the following words and phrases referring to key articles that evaluated the RWA in patients with prodromal or clinical α-synucleinopathy: “REM sleep behavior disorder”, “parasomnia”, “polysomnography”, “sleep monitoring”, “electromyography”, “muscle”, “quantitative”, “atonia”, “RWA”, “activity”, “tonic”, and “phasic”. We performed an initial search on November 9, 2021, using the following databases: MEDLINE, Embase, Web of Science, and the Cochrane Library. After reviewing the initial results, the authors (JI Byun, TW Yang, OY Kwon) discussed the search strategy and performed the final search on December 10, 2021. Databases were searched from inception to December 2021 for articles using keywords and Medical Subject Heading (MeSH) terms (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 1</ext-link></underline></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
      </sec>
      <sec id="s0002-s2003">
        <title>Selection Process</title>
        <p><citation_analysis attribute="positive">Two researchers (JI Byun and TW Yang) independently screened the relevant studies according to the titles and abstracts included in the search results. Subsequently, the same researchers selected studies for the meta-analysis after evaluating the full texts of the included articles to assess their eligibility. All authors discussed and came to a consensus regarding the selection criteria, and any disagreement was resolved by discussion and by the participation of an arbitrator (KY Jung) when necessary.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2004">
        <title>Data Collection Process</title>
        <p><citation_analysis attribute="positive">Data extraction was first performed by one researcher (JI Byun) and subsequently verified by the other two researchers (TW Yang and OY Kwon). RWA%-T and RWA%-P for meta-analyses were obtained using the data supplied in the included studies. For each study, the following data were also collected: study design, country, study groups, demographics, diagnostic criteria, disease duration and levodopa equivalent daily dose if applicable, REM sleep percentage, RWA criteria, and RWA%-T or RWA%-P.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2005">
        <title>Outcome</title>
        <p><citation_analysis attribute="neither">The target outcomes of this review were the mean differences (MDs) of RWA%-T and RWA%-P among α-synucleinopathy phenotypes.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2006">
        <title>Statistical Analysis</title>
        <p><citation_analysis attribute="positive">Effect sizes were obtained as the means and standard deviations from the primary studies. We first performed pairwise meta-analyses using a random-effects model for RWA%-T or RWA%-P between the study groups evaluated in three or more primary studies. Pooled estimates of MDs were calculated from each pair of groups. Heterogeneity in the pairwise comparisons was assessed using the </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">I<sup>2</sup></italic></citation_analysis><citation_analysis attribute="neither"> statistics for pooled MDs (0% indicating no heterogeneity, &gt;75% indicating substantial heterogeneity).</citation_analysis></p>
        <p><citation_analysis attribute="positive">We then performed NMAs to obtain rank probabilities for RWA%-T or RWA%-P among the α-synucleinopathy spectrum. The NMA using a Bayesian framework random-effect model was used to synthesize evidence by integrating direct and indirect estimates for each comparison into a single summary effect.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">MD along with its 95% credible interval (CrI) were calculated for each comparison using the Markov chain Monte Carlo method fitted using the Just Another Gibbs Samplers program.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="neither"> For the analysis, we used the Rjags</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither"> and gemtc</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither"> packages within R Statistical Software (version R i386 3.4.2, R project for Statistical Computing).</citation_analysis></p>
        <p><citation_analysis attribute="neither">The Bayesian model was run for 4 chains with an adaptive phase of 500 and a sampling phase of 10,000 iterations, thinned such that every 5th iteration was retained. Convergence was ensured by considering the Brooks–Gelman–Rubin diagnostics.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="neither"> Bayesian model fit was performed based on the deviance information criterion (DIC), a measure of goodness of fit and complexity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">We estimated the ranking probabilities of RWA%-T and RWA%-P using the surface under the cumulative ranking curve (SUCRA). The SUCRA score is expressed as a range of 0–1 (0 being the lowest percentage and 1 being the highest percentage of RWA). A common node splitting method of the gemtc package</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="negative"> was used to evaluate the inconsistency between direct and indirect comparisons.</citation_analysis></p>
        <p><citation_analysis attribute="positive">The physiological degeneration process could be a confounding factor for RWA%-T and RWA%-P. A significant age difference, if present, between the α-synucleinopathy phenotypes may provide a bias for NMA results. To control for age confounding, we also performed an additional NMA for the age of the phenotypes.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2007">
        <title>Quality Assessment of the Literature and Certainty of Evidence</title>
        <p><citation_analysis attribute="positive">The quality of each article was independently assessed by the two researchers (JI Byun and OY Kwon) using the Newcastle–Ottawa Scale (NOS).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="positive"> The NOS evaluates the following 8 domains: adequate case definition, representativeness of cases, selection of controls, definition of controls, comparability, ascertainment of exposure, same method and nonresponse rate. The total quality score ranged between 0 and 9. Studies assessed with ≥5 points were regarded as having a low risk of bias. Discordance between the authors was resolved by discussion with the third arbitrator (TW Yang) when necessary.</citation_analysis></p>
        <p><citation_analysis attribute="positive">To evaluate the certainty of the evidence obtained using pooled estimates of the pairwise meta-analyses, we used the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="positive"> using GRADEpro Guideline Development Tool (GRADEpro GDT) online software.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29</xref></citation_analysis><citation_analysis attribute="positive"> Two researchers (JI Byun and OY Kwon) independently assessed the quality, and any discordance was resolved by discussion with the third researcher (TW Yang).</citation_analysis></p>
      </sec>
      <sec sec-type="data-availability" id="s0002-s2008">
        <title>Data Availability</title>
        <p><citation_analysis attribute="neither">Data will be shared by request from any qualified investigator.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Results</title>
      <sec id="s0003-s2001">
        <title>Selected Studies</title>
        <p><citation_analysis attribute="positive">The detailed steps of the article selection process are shown in a PRISMA flow diagram (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0001" ref-type="fig">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">). We initially identified 1700 articles, and 1084 of them were retained after removing duplicates. A total of 41 articles were retrieved after an initial screening process that involved reviewing the titles and abstracts of the 1084 studies. The remaining 35 articles were examined in full-text form to select appropriate studies for this review. Finally, this evaluation found 15 studies that met the criteria of this review. </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 2</ext-link></underline></citation_analysis><citation_analysis attribute="neither"> lists the reasons for excluding the other 20 studies.
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p><citation_analysis attribute="neither">Flow diagram of the selection of the relevant studies.</citation_analysis></p></caption><graphic xlink:href="NSS-15-691-g0001" content-type="print-only" position="float"/><attrib><bold>Notes</bold>: A total of 1700 research articles were identified by searching five databases. Of these articles, 616 duplicate studies were removed, and an additional 1043 studies that did not satisfy the selection criteria were excluded from the analyses. The full texts of the remaining 35 studies were reviewed, and 20 of these were excluded for various reasons. Thus, a total of 15 studies were ultimately selected for the meta-analysis.</attrib><attrib><bold>Abbreviation</bold>: RBD, Rapid eye movement sleep behavior disorder.</attrib></fig></citation_analysis></p>
      </sec>
      <sec id="s0003-s2002">
        <title>Characteristics of the Included Studies</title>
        <p><citation_analysis attribute="positive">The features and data of the included studies are shown in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="positive">. Each of the 15 studies evaluated the group differences in RWA%-T or RWA%-P among the study groups, including various α-synucleinopathy phenotypes and controls. Regarding RWA%-T, one study compared it within the four groups,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> and five studies compared it among the three groups.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31–35</xref></citation_analysis><citation_analysis attribute="neither"> The remaining eight studies compared it between the two groups.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36–43</xref></citation_analysis><citation_analysis attribute="neither"> For each α-synucleinopathy phenotype, the number of recruited studies providing RWA%-T information was as follows: seven for iRBD (total patient number [tn]=196),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33–37</xref></citation_analysis><citation_analysis attribute="neither"> seven for PDwoRBD (tn=187),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41–43</xref></citation_analysis><citation_analysis attribute="neither"> ten for PDwtRBD (tn=286),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30–35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40–43</xref></citation_analysis><citation_analysis attribute="neither"> two for MSAwtRBD (tn=42),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> and one for DLBwtRBD (tn=9).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="positive"> Eight of the included studies provided information for the controls (tn=246).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34–40</xref></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0001" orientation="landscape"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Characteristics of the Studies Included in the Meta-Analysis</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Study</th><th rowspan="1" colspan="1">Country</th><th rowspan="1" colspan="1">D</th><th rowspan="1" colspan="1">N</th><th rowspan="1" colspan="1">Group</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">Age</th><th rowspan="1" colspan="1">Sex (M:F)</th><th rowspan="1" colspan="1">Dx. criteria</th><th rowspan="1" colspan="1">Ds Duration (Mean LEDD)</th><th rowspan="1" colspan="1">REM%</th><th rowspan="1" colspan="1">RWA Criteria<sup>a</sup></th><th rowspan="1" colspan="1">RWA%-T</th><th rowspan="1" colspan="1">RWA%-P</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Arnaldi 2016<xref rid="cit0030" ref-type="bibr">30</xref></td><td rowspan="1" colspan="1">France</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Control/iRBD/PDwoRBD/PDwtRBD</td><td rowspan="1" colspan="1">10/10/10/10</td><td rowspan="1" colspan="1">61±7/70±8/53±9/62±8</td><td rowspan="1" colspan="1">5:5/6:4/7:3/8:2</td><td rowspan="1" colspan="1">HC/ICSD-2/Gelb/Gelb</td><td rowspan="1" colspan="1">NA/NA/7.3±2.9(638)/9.8±3.7(773)</td><td rowspan="1" colspan="1">19.2±4.3/22.6±8.4/18.9±8.9/22.2±5.5</td><td rowspan="1" colspan="1">Tonic (30 sec), Phasic (3 sec)</td><td rowspan="1" colspan="1">1.6±1.5/52.7±17.7/4.1±2.9/22.9±14.6</td><td rowspan="1" colspan="1">0.9±1.0/35.5±12.9/2.1±4.3/12.2±7.1</td></tr><tr><td rowspan="1" colspan="1">Bugalho 2019<xref rid="cit0031" ref-type="bibr">31</xref></td><td rowspan="1" colspan="1">Portugal</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">iRBD/PDwtRBD/DLBwtRBD</td><td rowspan="1" colspan="1">20/23/9</td><td rowspan="1" colspan="1">70±9/68±1/79±9</td><td rowspan="1" colspan="1">17:3/14:9/6:3</td><td rowspan="1" colspan="1">ICSD-3/UKPDS/4th cons</td><td rowspan="1" colspan="1">NA/7.1±4.9(608)/NA</td><td rowspan="1" colspan="1">14.5±5.8/12.4±8.5/14.5±7.0</td><td rowspan="1" colspan="1">Tonic (30sec, ampx1.5), Phasic (3sec, ampx4)</td><td rowspan="1" colspan="1">21.5±21.7/34.8±26.6/19.6±18.2</td><td rowspan="1" colspan="1">35.9±21.0/27.2±22.3/30.3±28.7</td></tr><tr><td rowspan="1" colspan="1">Figorilli 2017<xref rid="cit0041" ref-type="bibr">41</xref></td><td rowspan="1" colspan="1">Italy</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">PDwoRBD/PDwtRBD</td><td rowspan="1" colspan="1">25/37</td><td rowspan="1" colspan="1">62±10/66±8</td><td rowspan="1" colspan="1">11:14/24:13</td><td rowspan="1" colspan="1">UKPDS/ICSD-3</td><td rowspan="1" colspan="1">8.0±5.0(796)/8.2±4.3(704)</td><td rowspan="1" colspan="1">13.7±8.2/10.5±5.5</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2), Phasic (3sec, ampx2)</td><td rowspan="1" colspan="1">10.0±7.9/58.5±20.1</td><td rowspan="1" colspan="1">3.6±2.3/11.8±8.1</td></tr><tr><td rowspan="1" colspan="1">Frauscher 2012<xref rid="cit0034" ref-type="bibr">34</xref></td><td rowspan="1" colspan="1">Austria, Spain</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Control/iRBD/PDwtRBD</td><td rowspan="1" colspan="1">30/15/15</td><td rowspan="1" colspan="1">67±9/66±8/68±8</td><td rowspan="1" colspan="1">25:5/12:3/8:7</td><td rowspan="1" colspan="1">OSA/ICSD-2/UKPDS</td><td rowspan="1" colspan="1">NA/9.4±9.3/7.5±7.2(NA)</td><td rowspan="1" colspan="1">20.1±6.2/16.5±6.6/18.1±8.5</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2), Phasic (3sec, ampx2)</td><td rowspan="1" colspan="1">1.4±1.9/36.8±28.7/66.8±30.4</td><td rowspan="1" colspan="1">7.3±3.7/38.8±20.8/42.9±17.5</td></tr><tr><td rowspan="1" colspan="1">Frauscher 2008<xref rid="cit0044" ref-type="bibr">44</xref></td><td rowspan="1" colspan="1">Austria, Spain</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">iRBD/PDwtRBD</td><td rowspan="1" colspan="1">8/9</td><td rowspan="1" colspan="1">68±4/54±9</td><td rowspan="1" colspan="1">7:1/6:3</td><td rowspan="1" colspan="1">ICSD-2/UKPDS</td><td rowspan="1" colspan="1">8.4±5.6/4.0±2.9(809)</td><td rowspan="1" colspan="1">NA/NA</td><td rowspan="1" colspan="1">Phasic (3sec, ampx2)</td><td rowspan="1" colspan="1">NA/NA</td><td rowspan="1" colspan="1">43.9±19.7/39.3±19.2</td></tr><tr><td rowspan="1" colspan="1">Garcia 2002<xref rid="cit0039" ref-type="bibr">39</xref></td><td rowspan="1" colspan="1">Spain</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Control/PDwoRBD</td><td rowspan="1" colspan="1">14/15</td><td rowspan="1" colspan="1">69±5/74±5</td><td rowspan="1" colspan="1">Match/9:6</td><td rowspan="1" colspan="1">SD/Gelb</td><td rowspan="1" colspan="1">NA/2.8±1.3(0)</td><td rowspan="1" colspan="1">NA/NA</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2), Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">1.4±1.9/0.5±1.4</td><td rowspan="1" colspan="1">5.4±4.6/2.0±2.5</td></tr><tr><td rowspan="1" colspan="1">Gong 2014<xref rid="cit0042" ref-type="bibr">42</xref></td><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">PDwoRBD/PDwtRBD</td><td rowspan="1" colspan="1">49/63</td><td rowspan="1" colspan="1">65±11/67±8</td><td rowspan="1" colspan="1">30:19/40:23</td><td rowspan="1" colspan="1">UKPDS/UKPDS</td><td rowspan="1" colspan="1">4.3±3.1(496)/4.8±3.6(510)</td><td rowspan="1" colspan="1">16.3±21.1/13.9±8.6</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2), Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">8.6±13.7/19.3±28.0</td><td rowspan="1" colspan="1">12.9±9.5/27.1±19.4</td></tr><tr><td rowspan="1" colspan="1">Gossard 2021<xref rid="cit0038" ref-type="bibr">38</xref></td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Control/PDwoRBD</td><td rowspan="1" colspan="1">27/23</td><td rowspan="1" colspan="1">71±9/71±10</td><td rowspan="1" colspan="1">22:5/18:5</td><td rowspan="1" colspan="1">SD/UKPDS</td><td rowspan="1" colspan="1">NA/NA (456)</td><td rowspan="1" colspan="1">19.0±6.5/22.2±9.8</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2)/Phasic (3sec, ampx4)</td><td rowspan="1" colspan="1">0.2±0.8/1.8±5.0</td><td rowspan="1" colspan="1">4.0±2.6/12.5±12.8</td></tr><tr><td rowspan="1" colspan="1">Iranzo 2005<xref rid="cit0033" ref-type="bibr">33</xref></td><td rowspan="1" colspan="1">Spain</td><td rowspan="1" colspan="1">CS</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">iRBD/PDwtRBD/MSAwtRBD</td><td rowspan="1" colspan="1">39/45/26</td><td rowspan="1" colspan="1">68±6/65±8/62±7</td><td rowspan="1" colspan="1">36:3/34:11/16:10</td><td rowspan="1" colspan="1">ICSD-2/UKPDS/1st cons</td><td rowspan="1" colspan="1">6.5±6.7/9.0±5.3(652)/4.5±2.3(398)</td><td rowspan="1" colspan="1">18.0±8.1/17.5±8.0/16.0±7.7</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2)/Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">39.0±36.0/39.4±31.6/68.8±29.3</td><td rowspan="1" colspan="1">27.2±16.0/22.1±11.2/30.6±20.0</td></tr><tr><td rowspan="1" colspan="1">Lee 2015<xref rid="cit0038" ref-type="bibr">38</xref></td><td rowspan="1" colspan="1">Korea</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Control/iRBD</td><td rowspan="1" colspan="1">15/17</td><td rowspan="1" colspan="1">60±9/65±7</td><td rowspan="1" colspan="1">9:6/10:7</td><td rowspan="1" colspan="1">SD/ICSD-3</td><td rowspan="1" colspan="1">NA/4.4</td><td rowspan="1" colspan="1">20.1±6.0/20.8±7.9</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2), Phasic (3sec, ampx4)</td><td rowspan="1" colspan="1">1.5±2.5/23.6±17.5</td><td rowspan="1" colspan="1">5.7±2.0/25.7±12.1</td></tr><tr><td rowspan="1" colspan="1">McCarter 2014<xref rid="cit0040" ref-type="bibr">40</xref></td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Control/PDwtRBD</td><td rowspan="1" colspan="1">40/20</td><td rowspan="1" colspan="1">68±9/69±8</td><td rowspan="1" colspan="1">33:7/20:0</td><td rowspan="1" colspan="1">OSA/ICSD-2, UKPDS</td><td rowspan="1" colspan="1">NA/6.0±5.0(829)</td><td rowspan="1" colspan="1">NA/NA</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2), Phasic (3sec, ampx4)</td><td rowspan="1" colspan="1">0.2±0.1/22.8±25.0</td><td rowspan="1" colspan="1">5.0±4.9/30.2±15.4</td></tr><tr><td rowspan="1" colspan="1">McCarter 2015<xref rid="cit0035" ref-type="bibr">35</xref></td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Control/iRBD/PDwtRBD</td><td rowspan="1" colspan="1">30/15/15</td><td rowspan="1" colspan="1">71±6/62±8/68±8</td><td rowspan="1" colspan="1">25:5/n.a./n.a.</td><td rowspan="1" colspan="1">OSA/ICSD-2/UKPDS</td><td rowspan="1" colspan="1">NA/6.1±5.8/8.1±5.5(NA)</td><td rowspan="1" colspan="1">21.1±6.4/NA/NA</td><td rowspan="1" colspan="1">Tonic (30sec, ampx2), Phasic (3sec, ampx4)</td><td rowspan="1" colspan="1">0/8.5±10.5/28.2±27.6</td><td rowspan="1" colspan="1">4.5±3.3/27.4±20.9/31.9±13.5</td></tr><tr><td rowspan="1" colspan="1">Montplaisir 2010<xref rid="cit0036" ref-type="bibr">36</xref></td><td rowspan="1" colspan="1">Canada</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Control/iRBD</td><td rowspan="1" colspan="1">80/80</td><td rowspan="1" colspan="1">61±12/63±10</td><td rowspan="1" colspan="1">62:18/62:18</td><td rowspan="1" colspan="1">HC/ICSD-1</td><td rowspan="1" colspan="1">NA/7.9±7.5</td><td rowspan="1" colspan="1">19.6±5.5/19.8±8.3</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2), Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">11.2±12.7/53.4±39.6</td><td rowspan="1" colspan="1">8.8±6.0/29.6±15.6</td></tr><tr><td rowspan="1" colspan="1">Shen 2017<xref rid="cit0043" ref-type="bibr">43</xref></td><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">PDwoRBD/PDwtRBD</td><td rowspan="1" colspan="1">53/40</td><td rowspan="1" colspan="1">61±1/68±9</td><td rowspan="1" colspan="1">35:18/28:12</td><td rowspan="1" colspan="1">UKPDS</td><td rowspan="1" colspan="1">3.5±2.8(230)/4.9±4.1(480)</td><td rowspan="1" colspan="1">15.7±6.8/15.7±7.5</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2), Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">1.9±2.7/30.9±37.0</td><td rowspan="1" colspan="1">6.4±6.3/44.1±31.4</td></tr><tr><td rowspan="1" colspan="1">Wang 2017<xref rid="cit0032" ref-type="bibr">32</xref></td><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">CC</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">PDwoRBD/PDwtRBD/MSAwtRBD</td><td rowspan="1" colspan="1">12/18/16</td><td rowspan="1" colspan="1">64±4/66±6/65±9</td><td rowspan="1" colspan="1">5:7/9:9/7:9</td><td rowspan="1" colspan="1">UKPDS/ICSD-2/2nd cons</td><td rowspan="1" colspan="1">2.5±1.4/4.5±2.7/3.3±1.7</td><td rowspan="1" colspan="1">NA/NA/NA</td><td rowspan="1" colspan="1">Tonic (20sec, ampx2), Phasic (2sec, ampx4)</td><td rowspan="1" colspan="1">2.7±4.1/13.6±9.6/50.1±34.8</td><td rowspan="1" colspan="1">1.9±1.1/9.7±8.1/12.6±17.6</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Notes</bold></citation_analysis><citation_analysis attribute="neither">: </citation_analysis><citation_analysis attribute="positive"><sup>a</sup></citation_analysis><citation_analysis attribute="neither">The following examples illustrate how to interpret the abbreviated descriptions of RWA criteria: Tonic (30sec, ampx1.5), tonic electromyographic (EMG) activity defined as the epoch of stage R with a duration of 30 seconds having an amplitude at least 1.5 times greater than the stage R atonia; Phasic (3sec, ampx4), phasic EMG activity defined as the epoch of stage R with a duration of 3 seconds having an amplitude at least 4 times greater than the stage R atonia.</citation_analysis></p></fn><fn id="tfn0002"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="positive">: NA, not available; D, design; CC, case–control study; CS, cross-sectional study; N, number of comparison arms; iRBD, isolated REM sleep behavior disorder; REM, rapid eye movement; PDwoRBD, Parkinson’s disease without RBD; PDwtRBD, PD with RBD; DLBwtRBD, dementia with Lewy bodies with RBD; MSAwtRBD, multiple system atrophy with RBD; n, number of patients or controls; M, male; F, female; Dx., diagnostic; HC, healthy control; ICSD, International Classification Sleep Disorder; Gelb, Gelb et al’s criteria for Parkinson’s disease; UKPDS, United Kingdom Parkinson’s Disease Brain Bank criteria; cons, consensus criteria; SD, sleep disorder control; OSA, obstructive sleep apnea; 1st con, first consensus; Ds, disease; LEDD, levodopa-equivalent daily dose; NA, not available; RWA, REM sleep without atonia; REM, rapid eye movement sleep; RBD, REM sleep behavior disorder; amp, amplitude; RWA%-T, RWA percentage during REM sleep evaluated by tonic chin activity; RWA%-P, percentage during REM sleep evaluated by phasic chin activity.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
        <p><citation_analysis attribute="neither">Concerning RWA%-P, one study compared it among four groups,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> and five studies compared it among three groups.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31–35</xref></citation_analysis><citation_analysis attribute="neither"> The remaining nine studies compared it between the two groups.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36–44</xref></citation_analysis><citation_analysis attribute="neither"> The number of studies that provided information for the RWA% for each type of α-synucleinopathy phenotype was as follows: eight for iRBD (tn=204),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33–37</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither"> seven for PDwoRBD (tn=187),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41–43</xref></citation_analysis><citation_analysis attribute="neither"> eleven for PDwtRBD (tn=295),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30–35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40–44</xref></citation_analysis><citation_analysis attribute="neither"> two for MSAwtRBD (tn=42),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> and one for DLBwtRBD (tn=9).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="positive"> Eight of the included studies provided information for the controls (tn=246).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34–40</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive"><xref rid="f0002" ref-type="fig">Figure 2</xref></citation_analysis><citation_analysis attribute="neither"> shows the network of eligible group comparisons for RWA%-T and RWA%-P. Each edge represents the presence of a direct comparison, and the thickness of the edges represents the number of direct comparisons. Groups with iRBD, PDwtRBD and PDwoRBD had at least one comparison with the control groups.
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p><citation_analysis attribute="neither">Network of eligible comparisons of REM sleep without atonia across the α-synucleinopathy spectrum. Each edge represents the presence of a direct comparison, and the thickness of the edges represents the number of direct comparisons. (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">) The most frequent combinations for direct comparison in RWA%-T were iRBD vs. controls, iRBD vs. PDwtRBD, and PDwoRBD vs. PDwtRBD (each n=5), followed by PDwtRBD vs. controls (n=4), PDwoRBD vs. controls (n=3), and PDwtRBD vs. MSAwtRBD (n=2). (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">) In phasic RWA, iRBD vs. PDwtRBD was the most frequent direct comparison (n=6), followed by iRBD vs. controls, PDwoRBD vs. PDwtRBD (each n=5), PDwtRBD vs. controls (n=4), PDwoRBD vs. controls (n=3), and PDwtRBD vs. MSAwtRBD (n=2). In other group pairs, only a single study or no study performed a direct comparison between the two groups.</citation_analysis></p></caption><graphic xlink:href="NSS-15-691-g0002" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: RWA%-T, RWA percentage during REM sleep evaluated by tonic chin activity; RWA%-P, RWA percentage during REM sleep evaluated by phasic chin activity; RBD, REM sleep behavior disorder; iRBD, isolated RBD; DLBwtRBD, dementia with Lewy bodies with RBD; PDwtRBD, Parkinson's disease with RBD; PDwoRBD, Parkinson's disease without RBD; MSAwtRBD, multiple system atrophy with RBD.</attrib></fig></citation_analysis></p>
        <p><citation_analysis attribute="neither">The most frequent direct comparisons in RWA%-T were iRBD vs controls</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34–37</xref></citation_analysis><citation_analysis attribute="neither"> and iRBD vs PDwtRBD</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33–35</xref></citation_analysis><citation_analysis attribute="neither"> (each n=5), followed by PDwtRBD vs controls</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40</xref></citation_analysis><citation_analysis attribute="neither"> and PDwoRBD vs PDwtRBD</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42</xref></citation_analysis><citation_analysis attribute="neither"> (each n=4), PDwoRBD vs controls (n=3),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> and PDwtRBD vs MSAwtRBD (n=2).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> In RWA%-P, iRBD vs PDwtRBD</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33–35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither"> was the most frequent direct comparison (n=6), followed by iRBD vs controls (n=5),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34–37</xref></citation_analysis><citation_analysis attribute="neither"> PDwtRBD vs controls</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40</xref></citation_analysis><citation_analysis attribute="neither"> and PDwoRBD vs PDwtRBD</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42</xref></citation_analysis><citation_analysis attribute="neither"> (each n=4), PDwoRBD vs controls (n=3),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> and PDwtRBD vs MSAwtRBD (n=2).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> In other group pairs, only a single study or no study performed a direct comparison between the two groups.</citation_analysis></p>
      </sec>
      <sec id="s0003-s2003">
        <title>Outcome of Pairwise Meta-Analysis</title>
        <p><citation_analysis attribute="neither">Detailed results of the pairwise meta-analyses are presented in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="positive">. Patients with iRBD and PDwtRBD had higher tonic or phasic RWA than controls. PDwtRBD showed a higher RWA%-T or RWA%-P than PDwoRBD. There was no significant difference observed during the direct comparison of the severity of REM atonia loss between PDwoRBD patients and controls or between iRBD patients and PDwtRBD patients.
</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0002"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Summary Estimates from Pairwise Meta-Analyses of Direct Comparisons of RWA%-T and RWA%-P</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Mean Difference in RWA%-T MD (95% CI)</th><th rowspan="1" colspan="1">Mean Difference in RWA%-P MD (95% CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">iRBD vs Controls</td><td rowspan="1" colspan="1"><bold>31.40 (16.24, 46.55)</bold></td><td rowspan="1" colspan="1"><bold>25.24 (19.31, 31.17)</bold></td></tr><tr><td rowspan="1" colspan="1">PDwoRBD vs Controls</td><td rowspan="1" colspan="1">0.92 (−1.16, 3.00)</td><td rowspan="1" colspan="1">1.78 (−4.79, 8.34)</td></tr><tr><td rowspan="1" colspan="1">PDwtRBD vs Controls</td><td rowspan="1" colspan="1"><bold>33.81 (13.91, 53.72)</bold></td><td rowspan="1" colspan="1"><bold>24.42 (14.37, 34.48)</bold></td></tr><tr><td rowspan="1" colspan="1">PDwtRBD vs PDwoRBD</td><td rowspan="1" colspan="1"><bold>23.47 (9.34, 37.60)</bold></td><td rowspan="1" colspan="1"><bold>14.95 (4.78, 25.12)</bold></td></tr><tr><td rowspan="1" colspan="1">PDwtRBD vs iRBD</td><td rowspan="1" colspan="1">6.17 (−13.99, 26.32)</td><td rowspan="1" colspan="1">−6.16 (−14.93, 2.60)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p><citation_analysis attribute="positive"><bold>Note</bold></citation_analysis><citation_analysis attribute="neither">: Bold font indicates statistical significance.</citation_analysis></p></fn><fn id="tfn0004"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="positive">: RWA%-T, RWA evaluated by tonic chin activity during REM sleep; RWA%-P, RWA evaluated by phasic chin activity during REM sleep; REM, rapid eye movement; RWA, REM sleep without atonia; MD, mean difference; CI, confidence interval; NA, not available, iRBD, isolated RBD; RBD, REM sleep behavior disorder; PDwtRBD, Parkinson’s disease with RBD; PDwoRBD, Parkinson’s disease without RBD.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis></p>
        <p><citation_analysis attribute="neither">The direct pairwise models showed substantial heterogeneity, with </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">I<sup>2</sup></italic></citation_analysis><citation_analysis attribute="neither"> values above 75% in all comparisons (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">I<sup>2</sup></italic></citation_analysis><citation_analysis attribute="neither"> values ranging from 79.2 to 95.1%) regarding the RWA%-T (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 3</ext-link></underline></citation_analysis><citation_analysis attribute="neither">). Except for the comparisons involving iRBD vs controls, all group comparisons in RWA%-P had </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">I<sup>2</sup></italic></citation_analysis><citation_analysis attribute="neither"> values above 75% (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">I<sup>2</sup></italic></citation_analysis><citation_analysis attribute="neither"> values varied from 31.1 to 90.9%) (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 4</ext-link></underline></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
      </sec>
      <sec id="s0003-s2004">
        <title>Outcome of NMA</title>
        <p><citation_analysis attribute="neither">The results of the NMA for RWA%-T and RWA%-P are presented as forest plots (</citation_analysis><citation_analysis attribute="positive"><xref rid="f0003" ref-type="fig">Figure 3</xref></citation_analysis><citation_analysis attribute="neither">) and tables (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0003 t0004" ref-type="table">Table 3 and 4</xref></citation_analysis><citation_analysis attribute="neither">, respectively). Regarding RWA%-T, the MSAwtRBD group showed a higher percentage than all of the other groups. The RWA%-T was the second highest in the PDwtRBD group, followed by the iRBD and DLBwtRBD groups. The RWA%-T was higher in the PDwoRBD groups than in the controls, but there was no statistical significance. Regarding the RWA%-P, iRBD had the highest percentage, followed by MSAwtRBD, DLBwtRBD, and PDwtRBD.
</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0003"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Table Showing Differences in RWA%-T Across the α-Synucleinopathy Spectrum</citation_analysis></p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1"><bold>Control</bold>*</td><td rowspan="1" colspan="1">0.92(−1.16, 3.00)<sup>‡</sup></td><td rowspan="1" colspan="1">§</td><td rowspan="1" colspan="1"><bold>31.40(16.24, 46.55)</bold></td><td rowspan="1" colspan="1"><bold>33.81(13.91, 53.72)</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">−2.26(−7.09, 2.50)<sup>†</sup></td><td rowspan="1" colspan="1"><bold>PDwoRBD</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>23.47(9.34, 37.60)</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−20.31(−36.41, −3.77)</bold></td><td rowspan="1" colspan="1"><bold>−17.95(−34.49, −1.23)</bold></td><td rowspan="1" colspan="1"><bold>DLBwtRBD</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−27.14(−32.58, −21.72)</bold></td><td rowspan="1" colspan="1"><bold>−24.89(−31.28, −18.38)</bold></td><td rowspan="1" colspan="1">−6.75(−23.19, 9.08)</td><td rowspan="1" colspan="1"><bold>iRBD</bold></td><td rowspan="1" colspan="1">−6.17(−13.99, 26.32)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−28.66(−33.97, −23.20)</bold></td><td rowspan="1" colspan="1"><bold>−26.42(−31.29, −21.42)</bold></td><td rowspan="1" colspan="1">−8.42(−24.96, 7.69)</td><td rowspan="1" colspan="1">−1.52(−8.07, 5.05)</td><td rowspan="1" colspan="1"><bold>PDwtRBD</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−56.93(−69.80, −44.08)</bold></td><td rowspan="1" colspan="1"><bold>−54.80(−67.19, −42.12)</bold></td><td rowspan="1" colspan="1"><bold>−36.78(−57.04, −16.78)</bold></td><td rowspan="1" colspan="1"><bold>−29.82(−42.76, −16.78)</bold></td><td rowspan="1" colspan="1"><bold>−26.42(−31.29, −21.42)</bold></td><td rowspan="1" colspan="1"><bold>MSAwtRBD</bold></td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><citation_analysis attribute="positive"><bold>Notes</bold></citation_analysis><citation_analysis attribute="neither">: *Groups are arranged from right to left in the order of their SUCRA values. Bold font indicates statistical significance. </citation_analysis><citation_analysis attribute="positive"><sup>†</sup></citation_analysis><citation_analysis attribute="neither">The lower triangle shows results from a network meta-analysis (including direct and indirect evidence) in terms of MDs and 95% CrIs for the groups in the columns vs groups in the rows. </citation_analysis><citation_analysis attribute="positive"><sup>‡</sup></citation_analysis><citation_analysis attribute="positive">The upper triangle shows results from pairwise meta-analyses in terms of MDs and 95% CIs for the groups in the rows vs the groups in the columns (direct evidence only). </citation_analysis><citation_analysis attribute="positive"><sup>§</sup></citation_analysis><citation_analysis attribute="neither">Some cells are empty because there were no studies examining the corresponding comparisons.</citation_analysis></p></fn><fn id="tfn0006"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="positive">: RWA%-T, RWA percentage during REM sleep evaluated by tonic chin activity; RWA, REM sleep without atonia; REM, rapid eye movement; PDwoRBD, Parkinson’s disease without RBD; RBD, REM sleep behavior disorder; iRWA, isolated RWA; DLBwtRBD, dementia with Lewy bodies with RBD; iRBD, isolated RBD; PDwtRBD, PD with RBD; MSAwtRBD, multiple system atrophy with RBD; SUCRA, surface under the cumulative ranking curve; MD, mean difference; CrI, credible interval; CI, confidence interval.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><table-wrap position="float" id="t0004"><label>Table 4</label><caption><p><citation_analysis attribute="neither">Table Showing Differences in RWA%-P Across the α-Synucleinopathy Spectrum</citation_analysis></p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="1" colspan="1"><bold>Control</bold>*</td><td rowspan="1" colspan="1">1.78(−4.79, 8.34)<sup>‡</sup></td><td rowspan="1" colspan="1"><bold>24.42(14.37, 34.48)</bold></td><td rowspan="1" colspan="1">§</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><bold>25.24(19.31, 31.17)</bold></td></tr><tr><td rowspan="1" colspan="1">−4.44(−9.01, 0.17)<sup>†</sup></td><td rowspan="1" colspan="1"><bold>PDwoRBD</bold></td><td rowspan="1" colspan="1"><bold>9.26(7.05, 11.47)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−20.20(−24.55, −15.78)</bold></td><td rowspan="1" colspan="1"><bold>−15.74(−19.90, −11.61)</bold></td><td rowspan="1" colspan="1"><bold>PDwtRBD</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6.16(−2.60, 14.93)</td></tr><tr><td rowspan="1" colspan="1">−21.20(−43.05, 0.85)</td><td rowspan="1" colspan="1">−16.71(−38.53, 5.35)</td><td rowspan="1" colspan="1">−0.94(−22.58, 21.20)</td><td rowspan="1" colspan="1"><bold>DLBwtRBD</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−23.37(−32.34, −14.22)</bold></td><td rowspan="1" colspan="1"><bold>−19.03(−27.52, −10.07)</bold></td><td rowspan="1" colspan="1">−3.28(−11.51, 5.28)</td><td rowspan="1" colspan="1">−2.44(−25.69, 20.84)</td><td rowspan="1" colspan="1"><bold>MSAwtRBD</bold></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"><bold>−25.20(−29.75, −20.58)</bold></td><td rowspan="1" colspan="1"><bold>−20.75(−26.32, −15.19)</bold></td><td rowspan="1" colspan="1"><bold>−5.01(−10.02, −0.07)</bold></td><td rowspan="1" colspan="1">−4.17(−26.21, 17.82)</td><td rowspan="1" colspan="1">−1.81(−11.09, 7.10)</td><td rowspan="1" colspan="1"><bold>iRBD</bold></td></tr></tbody></table><table-wrap-foot><fn id="tfn0007"><p><citation_analysis attribute="positive"><bold>Notes</bold></citation_analysis><citation_analysis attribute="neither">: *Groups are arranged from right to left in the order of their SUCRA values. Bold font indicates statistical significance. </citation_analysis><citation_analysis attribute="positive"><sup>†</sup></citation_analysis><citation_analysis attribute="neither">The lower triangle shows results from a network meta-analysis (including direct and indirect evidence) in terms of MDs and 95% CrIs for the groups in the columns vs groups in the rows. </citation_analysis><citation_analysis attribute="positive"><sup>‡</sup></citation_analysis><citation_analysis attribute="positive">The upper triangle shows results from pairwise meta-analyses in terms of MDs and 95% CIs for the groups in the rows vs the groups in the columns (direct evidence only). </citation_analysis><citation_analysis attribute="positive"><sup>§</sup></citation_analysis><citation_analysis attribute="neither">Some cells are empty because there were no studies examining the corresponding comparisons.</citation_analysis></p></fn><fn id="tfn0008"><p><citation_analysis attribute="positive"><bold>Abbreviations</bold></citation_analysis><citation_analysis attribute="positive">: RWA%P, RWA percentage during REM sleep evaluated by phasic chin activity; RWA, REM sleep without atonia; REM, rapid eye movement; iRWA, isolated RWA; PDwoRBD, Parkinson’s disease without RBD; RBD, REM sleep behavior disorder; PDwtRBD, PD with RBD; DLBwtRBD, dementia with Lewy bodies with RBD; MSAwtRBD, multiple system atrophy with RBD; iRBD, isolated RBD; SUCRA, surface under the cumulative ranking curve; MD, mean difference; CrI, credible interval; CI, confidence interval.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p><citation_analysis attribute="positive">Forest plot of network meta-analysis for RWA percentage during REM sleep evaluated by tonic chin activity (RWA%-T) or phasic chin activity (RWA%-P) among the α-synucleinopathies spectrum. (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">) Regarding RWA%-T, the MSAwtRBD group showed a higher percentage than all other groups. The RWA%-T was the second highest in the PDwtRBD group, followed by iRBD and DLBwtRBD. The RWA%-T was higher in PDwoRBD patients than in controls, but there was no statistical significance. (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="positive">) Regarding the RWA%-P, iRBD had the highest percentage, followed by MSAwtRBD, DLBwtRBD, and PDwtRBD. There was no significant difference between the DLBwtRBD patients and the controls.</citation_analysis></p></caption><graphic xlink:href="NSS-15-691-g0003" content-type="print-only" position="float"/><attrib><bold>Abbreviations</bold>: RWA%-T, RWA percentage during REM sleep evaluated by tonic chin activity; RWA%-P, RWA percentage during REM sleep evaluated by phasic chin activity; RBD, REM sleep behavior disorder; iRBD, isolated RBD; DLBwtRBD, dementia with Lewy bodies with RBD; PDwtRBD, Parkinson's disease with RBD; PDwoRBD, Parkinson's disease without RBD; MSAwtRBD, multiple system atrophy with RBD.</attrib></fig></citation_analysis></p>
        <p><citation_analysis attribute="neither">The rank probabilities of RWA%-T and RWA%-P based on SUCRA are presented in </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 5</ext-link></underline></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Figure 3</ext-link></underline></citation_analysis><citation_analysis attribute="neither">. Regarding the RWA%-T, the MSAwtRBD group (SUCRA 1.000) had the highest rank, followed by PDwtRBD (SUCRA 0.709), iRBD (SUCRA 0.621), DLBwtRBD (SUCRA 0.465), and PDwoRBD (SUCRA 0.168). Regarding the RWA%-P, iRBD (SUCRA 0.855) had the highest rank, followed by MSAwtRBD (SUCRA 0.742), DLBwtRBD (SUCRA 0.639), PDwtRBD (SUCRA 0.543), and PDwoRBD (SUCRA 0.209).</citation_analysis></p>
        <p><citation_analysis attribute="neither">Looking at the ranking probabilities obtained from the network meta-analysis, the ranking probabilities of RWA%-T were more than 50% in all rankings, and the ordering was distinct. On the other hand, those of RWA%-P were lower than 50% from the first to fourth ranks, and the orders were ambiguous (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Figure 1</ext-link></underline></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
        <p><citation_analysis attribute="positive">The mean age of each group was 65.5±10.4 for iRBD, 64.2±9.3 for PDwoRBD, 66.3±8.0 for PDwtRBD, 63.1±7.9 for MSAwtRBD, 79±9 for DLBwtRBD, and 65.6±10.4 for the controls. NMA revealed no significant age difference between controls and α-synucleinopathy phenotypes, except for DLBwtRBD, of which age was higher than the controls or PDwoRBD. However, the significance of the age difference should be further investigated because only a single study evaluated DLBwtRBD. We further performed an exploratory pairwise comparison of disease duration in studies that compared PDwtRBD and PDwoRBD. The disease duration in PDwtRBD (5.8±4.1) was longer than that in PDwoRBD (4.7±3.7, p=0.015). The MD of age between the two groups was 1.2 years with a 95% confidence interval of 0.5–1.9 years.</citation_analysis></p>
      </sec>
      <sec id="s0003-s2005">
        <title>Quality of the Included Studies</title>
        <p><citation_analysis attribute="positive">Methodological quality was assessed using NOS scores, and the results are presented in </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Table 6</ext-link></underline></citation_analysis><citation_analysis attribute="negative">. All of the studies had NOS scores greater than or equal to 5, indicating that all studies had a low risk for bias. The NOS score was 8 in one study,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither"> 7 in eight studies,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39–42</xref></citation_analysis><citation_analysis attribute="neither"> 6 in four studies,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither"> and 5 in the rest.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither"> Star was not awarded in terms of the “representativeness of cases” in two studies</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither"> because of the retrospective selection of patients. Only three studies</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="positive"> were awarded a star in the “Selection of Controls” because most studies included hospital controls. Regarding “comparability”, only one star was awarded in four studies,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0043" ref-type="bibr">43</xref></citation_analysis><citation_analysis attribute="neither"> and the star was not awarded in another two studies</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither"> because of group differences in age, sex or both.</citation_analysis></p>
      </sec>
      <sec id="s0003-s2006">
        <title>Assessment of Inconsistency</title>
        <p><citation_analysis attribute="positive">We used the node-splitting model to assess the inconsistency between direct and indirect comparisons. The null hypothesis of consistency can be excluded when p&lt;0.05 in the tests. Regarding the RWA%-T, the inconsistency test revealed no significant disagreement between any direct and indirect comparisons (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Figure 2</ext-link></underline></citation_analysis><citation_analysis attribute="positive">). Regarding the RWA%-P, the test indicated no significant discrepancy in all but one pair. The pair of PDwtRBD and PDwoRBD was the only pair that showed significant inconsistency (p=0.036) (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Figure 3</ext-link></underline></citation_analysis><citation_analysis attribute="neither">). The DIC values for RWA%-T and RWA%-P were 92.81 and 76.08, respectively.</citation_analysis></p>
      </sec>
      <sec id="s0003-s2007">
        <title>Evaluation of Evidence Certainty for the Outcomes</title>
        <p><citation_analysis attribute="positive">Most of the certainty of evidence for the pooled estimates was graded as “very low” because of a serious or very serious risk for bias due to patient selection and an inconsistency between the included studies and imprecision due to wide confidence intervals (</citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">Supplementary Tables 7</ext-link></underline></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=423878.doc" ext-link-type="uri">8</ext-link></underline></citation_analysis><citation_analysis attribute="neither">).</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Discussion</title>
      <p><citation_analysis attribute="positive">This review evaluated 15 studies that compared RWA%-T or RWA%-P among prodromal or overt α-synucleinopathy phenotypes and controls. All other groups except PDwoRBD had higher RWA%-T than controls. RWA%-P was more elevated in the other groups, except for PDwoRBD and DLBwtRBD, than in the controls. Looking at the rank orders obtained from this review and their statistical significance, we can see this relationship. Compared with the controls, RWA%-T was higher in all groups with RBD but was comparable in PDwoRBD. The rank of RWA%-T was highest in RBD patients with MSA, followed by those with PD and iRBD patients. In contrast, the ranking probabilities and the surface under the cumulative ranking displayed the iRBD as the first for RWA%-P. Previous reports showed that RWA%-T was more closely associated with neurodegeneration than RWA%-P.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The difference in the rank order between RWA%-T and RWA%-P may be due to the different pathomechanisms of these two forms of RWA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither"> RWA%-T is associated with degeneration of the sublaterodorsal nucleus,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="positive"> which is suggested to be associated with an increased risk for PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="positive"> Studies have shown that increased RWA%-T in iRBD is associated with future progression to α-synucleinopathy phenotypes.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0045" ref-type="bibr">45</xref></citation_analysis><citation_analysis attribute="neither"> RWA%-P, however, is related to changes in intermediate ventromedial medulla pathways.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, RWA%-P is more readily influenced by medications, such as levodopa</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> or antidepressants,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0046" ref-type="bibr">46</xref></citation_analysis><citation_analysis attribute="neither"> than RWA%-T.</citation_analysis></p>
      <p><citation_analysis attribute="positive">This review showed that MSAwtRBD had the highest RWA%-T among α-synucleinopathy phenotypes. This observation was consistent with the pathomechanism of MSA. Unlike PD, which affects neurons in selected brain regions, MSA affects oligodendroglia throughout the brain in the form of α-synuclein-positive glial cytoplasmic inclusions.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0047" ref-type="bibr">47</xref></citation_analysis><citation_analysis attribute="neither"> MSA patients may have higher RWA%-T than patients with the other α-synucleinopathy phenotypes because of diffuse brainstem involvement. Due to symptom overlap, MSA is often misdiagnosed as PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0048" ref-type="bibr">48</xref></citation_analysis><citation_analysis attribute="positive"> RWA%-T may assist in distinguishing MSAwtRBD from PDwtRBD, as suggested in a previous study.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">In this review, the RWA%-T in DLBwtRBD ranked lower than that in iRBD or PDwtRBD. Moreover, their RWA%-P increment was not statistically significant compared to the controls. Statistics might have distorted the results because a single included study evaluated a small amount of DLBwtRBD patient data. There is, however, a plausible explanation for the results. In PD, two subtypes are suggested according to the propagation of α-synucleinopathy: the brain-first and body-first subtypes.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0049" ref-type="bibr">49</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis><citation_analysis attribute="neither"> The pathologic progression of DLB may mimic the brain-first type, with pathologic alterations first appearing in the brain and then spreading to the brainstem. Consequently, in the early disease stage of DLB, dementia, rather than motor symptoms, is predominant.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0051" ref-type="bibr">51</xref></citation_analysis><citation_analysis attribute="negative"> A previous study found that the severity of REM atonia loss measured by chin tonic activity was linked to the risk for PD but not for dementia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The loss of REM sleep atonia in PD may be related to specific neurodegenerative alterations affecting certain brainstem neurons.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither"> The α-synuclein pathology in some PD takes anatomic routes that differ from those described in the Braak model.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="neither"> They could be the brain-first PD patients who develop parkinsonism before losing REM sleep atonia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0049" ref-type="bibr">49</xref></citation_analysis><citation_analysis attribute="positive"> The presence of RWA is reported in 40–75% of PD patients, and DEB is reported in only 50–58% of patients with RWA.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0010" ref-type="bibr">10</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0043" ref-type="bibr">43</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0054" ref-type="bibr">54</xref></citation_analysis><citation_analysis attribute="positive"> In this review, the loss of REM sleep atonia did not differ between PDwoRBD patients and controls. The findings might support that the RWA in PD is not an intrinsic characteristic but an epiphenomenon of specific anatomical involvement.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">PDwtRBD patients showed increased RWA%-T and RWA%-P compared to PDwoRBD patients and controls. Because excessive RWA is required for the diagnosis of RBD, the result was to be expected and was consistent with previous studies.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0043" ref-type="bibr">43</xref></citation_analysis><citation_analysis attribute="neither"> RBD in PD is associated with more severe motor or nonmotor symptoms and a longer duration of PD.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0055" ref-type="bibr">55</xref></citation_analysis><citation_analysis attribute="neither"> RWA in PD patients was also associated with disease duration and motor or nonmotor disease severity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0056" ref-type="bibr">56</xref></citation_analysis><citation_analysis attribute="positive"> In line with these reports, comparison of disease duration using primary studies of this review showed significantly longer disease duration in PDwtRBD than in PDwoRBD.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Several limitations should be considered when interpreting the results of our meta-analysis. We could not evaluate how the RWA% increased as neurodegeneration progressed because most included studies were cross-sectional studies rather than longitudinal studies. There was significant bias in patient selection because of the retrospective nature of the studies. Specific criteria for RWA% quantification may vary between the studies; however, they overall rate the percentage of RWA during REM sleep. Moreover, due to a lack of studies, we could not include studies providing information on MSA or DLB patients who did not have RBD. This meta-analysis did not evaluate the possible effects of confounders such as medication, comorbid sleep disorders, or ethnic differences. Future prospective and well-controlled longitudinal studies may be helpful in better understanding the relationship between RWA%-T and neurodegenerative processes.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Because most studies evaluating RWA have used tonic or phasic chin muscle activity until now, we only used the information using chin EMG for the NMA. Future research may reveal more subtle changes associated with neurodegeneration by evaluating RWA% with mixed RWA, which best predicts phenoconversion in iRBD,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither"> or by additionally considering upper limb muscle activity, which has higher diagnostic value than chin EMG alone.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0057" ref-type="bibr">57</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0058" ref-type="bibr">58</xref></citation_analysis><citation_analysis attribute="negative"> If information from other studies additionally considering mixed RWA, upper limb muscle activity or combined muscle activities becomes sufficient, a more sophisticated NMA evaluation of the relationship between RWA and the α-synucleinopathy spectrum would be conceivable.</citation_analysis></p>
    </sec>
    <sec id="s0005">
      <title>Conclusions</title>
      <p><citation_analysis attribute="neither">In this NMA, we compared RWA%-T and RWA%-P between or among the various prodromal or overt α-synucleinopathy phenotypes. MSAwtRBD had the highest RWA%-T, followed by PDwtRBD, iRBD, and DLBwtRBD. Meanwhile, the RWA%-P was highest in iRBD, and the rank orders in RWA%-P were unclear. As a result, RWA%-T seemed to reflect the neurodegenerative process in RBD patients, but RWA%-P may not. In addition, RWA%-T and RWA%-P were lower in PDwoRBD than in PDwtRBD and comparable to controls. More research will be needed to understand the pathomechanism of REM atonia loss in PD.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <sec id="s0006">
      <title>Abbreviations</title>
      <p><citation_analysis attribute="neither">REM, rapid eye movement; iRBD, isolated REM sleep behavior disorder; PD, Parkinson’s disease; DLB, dementia with Lewy bodies; MSA, multiple system atrophy; RWA, REM sleep without atonia.</citation_analysis></p>
    </sec>
    <sec id="s0007">
      <title>Data Sharing Statement</title>
      <p><citation_analysis attribute="neither">Data are available from the corresponding author upon reasonable request.</citation_analysis></p>
    </sec>
    <sec id="s0008">
      <title>Trial Registration Information</title>
      <p><citation_analysis attribute="neither">This study was prospectively registered in PROSPERO under registration number CRD42021276445.</citation_analysis></p>
    </sec>
    <sec id="s0009">
      <title>Author Contributions</title>
      <p><citation_analysis attribute="positive">All authors made significant contributions to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or all these areas. Additionally, all took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</citation_analysis></p>
    </sec>
    <sec sec-type="COI-statement" id="s0010">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">The authors report no conflicts of interest in this work.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Boeve</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Saper</surname>
<given-names>CB</given-names></string-name>, et al. <article-title>Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2007</year>;<volume>130</volume>(<issue>11</issue>):<fpage>2770</fpage>–<lpage>2788</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awm056</pub-id><pub-id pub-id-type="pmid">17412731</pub-id></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Högl</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Stefani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Videnovic</surname>
<given-names>A</given-names></string-name>. <article-title>Idiopathic REM sleep behaviour disorder and neurodegeneration—an update</article-title>. <source><italic toggle="yes">Nat Rev Neurol</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrneurol.2017.157</pub-id><pub-id pub-id-type="pmid">29170501</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>You</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jeon</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>YW</given-names></string-name>. <article-title>Rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">J Sleep Med</italic></source>. <year>2018</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.13078/jsm.18001</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2019</year>;<volume>142</volume>(<issue>3</issue>):<fpage>744</fpage>–<lpage>759</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awz030</pub-id><pub-id pub-id-type="pmid">30789229</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Galbiati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Verga</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Giora</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zucconi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ferini-Strambi</surname>
<given-names>L</given-names></string-name>. <article-title>The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2019</year>;<volume>43</volume>:<fpage>37</fpage>–<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2018.09.008</pub-id><pub-id pub-id-type="pmid">30503716</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miglis</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Adler</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Antelmi</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2021</year>;<volume>20</volume>(<issue>8</issue>):<fpage>671</fpage>–<lpage>684</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(21)00176-9</pub-id><pub-id pub-id-type="pmid">34302789</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCann</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Cartwright</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Halliday</surname>
<given-names>GM</given-names></string-name>. <article-title>alpha-synucleinopathy phenotypes</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2014</year>;<volume>20</volume>(<issue>Suppl 1</issue>):<fpage>S62</fpage>–<lpage>S67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1353-8020(13)70017-8</pub-id><pub-id pub-id-type="pmid">24262191</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Howell</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Schenck</surname>
<given-names>CH</given-names></string-name>. <article-title>Rapid eye movement sleep behavior disorder and neurodegenerative disease</article-title>. <source><italic toggle="yes">JAMA Neurol</italic></source>. <year>2015</year>;<volume>72</volume>(<issue>6</issue>):<fpage>707</fpage>–<lpage>712</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2014.4563</pub-id><pub-id pub-id-type="pmid">25867792</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Boeve</surname>
<given-names>BF</given-names></string-name>. <article-title>REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions</article-title>. <source><italic toggle="yes">Ann N Y Acad Sci</italic></source>. <year>2010</year>;<volume>1184</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.05115.x</pub-id><pub-id pub-id-type="pmid">20146689</pub-id></mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dijkstra</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Van den Bossche</surname>
<given-names>K</given-names></string-name>, <string-name><surname>de Bruyn</surname>
<given-names>B</given-names></string-name>, et al. <article-title>REM sleep without atonia and the relation with Lewy body disease</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2019</year>;<volume>67</volume>:<fpage>90</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2019.07.007</pub-id><pub-id pub-id-type="pmid">31326237</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ratti</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Casanova-Molla</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Serradell</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Vilaseca</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>. <article-title>Excessive muscle activity increases over time in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1149</fpage>–<lpage>1153</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.9.1149</pub-id><pub-id pub-id-type="pmid">19750919</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Rompre</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>JY</given-names></string-name>. <article-title>Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2010</year>;<volume>74</volume>(<issue>3</issue>):<fpage>239</fpage>–<lpage>244</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ca0166</pub-id><pub-id pub-id-type="pmid">20083800</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nepozitek</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dostalova</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dusek</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Simultaneous tonic and phasic REM sleep without atonia best predicts early phenoconversion to neurodegenerative disease in idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>;<volume>42</volume>(<issue>9</issue>):<fpage>zsz132</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz132</pub-id><pub-id pub-id-type="pmid">31194249</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chau</surname>
<given-names>SWH</given-names></string-name>, et al. <article-title>Evolution of prodromal REM sleep behavior disorder to neurodegeneration: a Retrospective Longitudinal Case-Control Study</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2022</year>;<volume>99</volume>(<issue>6</issue>):<fpage>e627</fpage>–<lpage>e637</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000200707</pub-id><pub-id pub-id-type="pmid">35550550</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Clinical correlates of rapid eye movement sleep without atonia in Parkinson’s disease</article-title>. <source><italic toggle="yes">Clin Neurophysiol</italic></source>. <year>2015</year>;<volume>126</volume>(<issue>6</issue>):<fpage>1198</fpage>–<lpage>1203</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinph.2014.09.014</pub-id><pub-id pub-id-type="pmid">25449561</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>de Natale</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Politis</surname>
<given-names>M</given-names></string-name>. <article-title>Predictors of RBD progression and conversion to synucleinopathies</article-title>. <source><italic toggle="yes">Curr Neurol Neurosci Rep</italic></source>. <year>2022</year>;<volume>22</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11910-022-01171-0</pub-id><pub-id pub-id-type="pmid">35274191</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Antoniou</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Koelemay</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Antoniou</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Mavridis</surname>
<given-names>D</given-names></string-name>. <article-title>A practical guide for application of network meta-analysis in evidence synthesis</article-title>. <source><italic toggle="yes">Eur J Vasc Endovasc Surg</italic></source>. <year>2019</year>;<volume>58</volume>(<issue>1</issue>):<fpage>141</fpage>–<lpage>144</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejvs.2018.10.023</pub-id><pub-id pub-id-type="pmid">30528457</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rouse</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Chaimani</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>. <article-title>Network meta-analysis: an introduction for clinicians</article-title>. <source><italic toggle="yes">Intern Emerg Med</italic></source>. <year>2017</year>;<volume>12</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>111</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11739-016-1583-7</pub-id><pub-id pub-id-type="pmid">27913917</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Page</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>McKenzie</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Bossuyt</surname>
<given-names>PM</given-names></string-name>, et al. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2021</year>;<volume>372</volume>:<fpage>n71</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wan</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tong</surname>
<given-names>T</given-names></string-name>. <article-title>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</article-title>. <source><italic toggle="yes">BMC Med Res Methodol</italic></source>. <year>2014</year>;<volume>14</volume>:<fpage>135</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2288-14-135</pub-id><pub-id pub-id-type="pmid">25524443</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sutton</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Abrams</surname>
<given-names>KR</given-names></string-name>. <article-title>Bayesian methods in meta-analysis and evidence synthesis</article-title>. <source><italic toggle="yes">Stat Methods Med Res</italic></source>. <year>2001</year>;<volume>10</volume>(<issue>4</issue>):<fpage>277</fpage>–<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1177/096228020101000404</pub-id><pub-id pub-id-type="pmid">11491414</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="book"><string-name><surname>Plummer</surname>
<given-names>M</given-names></string-name>. <source><italic toggle="yes">JAGS Version 3.3. 0 User Manual</italic></source>. <publisher-name>International Agency for Research on Cancer</publisher-name>; <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="newspaper"><string-name><surname>Rjags</surname>
<given-names>P</given-names></string-name>. <article-title>Bayesian graphical models using MCMC</article-title>. <source>R package version 4-12</source>; <year>2021</year>.</mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="webpage"><string-name><surname>van Valkenhoef</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kuiper</surname>
<given-names>J</given-names></string-name>. <article-title>gemtc: network meta-analysis using Bayesian methods</article-title>. <source>R package version 1.0–1</source>. <comment>Available from:</comment>
<ext-link xlink:href="https://CRAN.R-project.org/package=gemtc" ext-link-type="uri">https://CRAN.R-project.org/package=gemtc</ext-link>. <date-in-citation>Accessed <month>August</month>
<day>24</day>, 2023</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Brooks</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Gelman</surname>
<given-names>A</given-names></string-name>. <article-title>General methods for monitoring convergence of iterative simulations</article-title>. <source><italic toggle="yes">J Comput Graph Stat</italic></source>. <year>1998</year>;<volume>7</volume>(<issue>4</issue>):<fpage>434</fpage>–<lpage>455</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10618600.1998.10474787</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Spiegelhalter</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Best</surname>
<given-names>NG</given-names></string-name>, <string-name><surname>Carlin</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Van der linde</surname>
<given-names>A</given-names></string-name>. <article-title>Bayesian measures of model complexity and fit</article-title>. <source><italic toggle="yes">J R Stat Soc Ser B</italic></source>. <year>2002</year>;<volume>64</volume>(<issue>4</issue>):<fpage>583</fpage>–<lpage>639</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1467-9868.00353</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="webpage"><string-name><surname>Wells</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Shea</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Connell</surname>
<given-names>DO</given-names></string-name>, et al. <article-title>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</article-title>. <comment>Available from:</comment>
<ext-link xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" ext-link-type="uri">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link>. <date-in-citation>Accessed <month>August</month>
<day>8</day>, 2023</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="webpage"><string-name><surname>Schünemann</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Brożek</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guyatt</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Oxman</surname>
<given-names>A</given-names></string-name>
<article-title>GRADE handbook for grading quality of evidence and strength of recommendations</article-title>. <comment>Available from:</comment>
<ext-link xlink:href="https://gdt.gradepro.org/app/handbook/handbook.html" ext-link-type="uri">https://gdt.gradepro.org/app/handbook/handbook.html</ext-link>. <date-in-citation>Accessed <month>August</month>
<day>15</day>, 2019</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="book"><collab>University and Evidence Prime</collab>. <source><italic toggle="yes">GRADEpro GDT: GRADEpro Guideline Development Tool [Software]</italic></source>. <publisher-name>University and Evidence Prime</publisher-name>; <year>2021</year>.</mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arnaldi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Latimier</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Leu-Semenescu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>De Carli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Vidailhet</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>. <article-title>Does postural rigidity decrease during REM sleep without atonia in Parkinson disease?</article-title>
<source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2016</year>;<volume>12</volume>(<issue>6</issue>):<fpage>839</fpage>–<lpage>847</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.5882</pub-id><pub-id pub-id-type="pmid">26857056</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bugalho</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Salavisa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marto</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Borbinha</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Alves</surname>
<given-names>L</given-names></string-name>. <article-title>Polysomnographic data in Dementia with Lewy bodies: correlation with clinical symptoms and comparison with other α-synucleinopathies</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2019</year>;<volume>55</volume>:<fpage>62</fpage>–<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2018.12.006</pub-id><pub-id pub-id-type="pmid">30772695</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>KP</given-names></string-name>, et al. <article-title>Tonic electromyogram density in multiple system atrophy with predominant Parkinsonism and Parkinson’s disease</article-title>. <source><italic toggle="yes">Chin Med J</italic></source>. <year>2017</year>;<volume>130</volume>(<issue>6</issue>):<fpage>684</fpage>–<lpage>690</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0366-6999.201603</pub-id><pub-id pub-id-type="pmid">28303851</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rye</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2005</year>;<volume>65</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>252</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000168864.97813.e0</pub-id><pub-id pub-id-type="pmid">16043794</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Frauscher</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gaig</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2012</year>;<volume>35</volume>(<issue>6</issue>):<fpage>835</fpage>–<lpage>847</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.1886</pub-id><pub-id pub-id-type="pmid">22654203</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>St. Louis</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Sandness</surname>
<given-names>DJ</given-names></string-name>, et al. <article-title>Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2015</year>;<volume>38</volume>(<issue>6</issue>):<fpage>907</fpage>–<lpage>917</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.4738</pub-id><pub-id pub-id-type="pmid">25325487</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Fantini</surname>
<given-names>ML</given-names></string-name>, et al. <article-title>Polysomnographic diagnosis of idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2010</year>;<volume>25</volume>(<issue>13</issue>):<fpage>2044</fpage>–<lpage>2051</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.23257</pub-id><pub-id pub-id-type="pmid">20818653</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lee</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>CU</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>GH</given-names></string-name>. <article-title>Quantitative EMG criteria for diagnosing idiopathic REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2015</year>;<volume>19</volume>(<issue>2</issue>):<fpage>685</fpage>–<lpage>691</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-014-1077-7</pub-id><pub-id pub-id-type="pmid">25395265</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gossard</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Gorres</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Quantitative REM Sleep without atonia in Parkinson’s disease and essential tremor</article-title>. <source><italic toggle="yes">Mov Disord Clin Pract</italic></source>. <year>2021</year>;<volume>8</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mdc3.13112</pub-id><pub-id pub-id-type="pmid">33426157</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Garcia-Borreguero</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Caminero</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>De La Llave</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Decreased phasic EMG activity during rapid eye movement sleep in treatment-naive Parkinson’s disease: effects of treatment with levodopa and progression of illness</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2002</year>;<volume>17</volume>(<issue>5</issue>):<fpage>934</fpage>–<lpage>941</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.10233</pub-id><pub-id pub-id-type="pmid">12360542</pub-id></mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McCarter</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>St. Louis</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Duwell</surname>
<given-names>EJ</given-names></string-name>, et al. <article-title>Diagnostic thresholds for quantitative REM sleep phasic burst duration, phasic and tonic muscle activity, and REM atonia index in REM sleep behavior disorder with and without comorbid obstructive sleep apnea</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2014</year>;<volume>37</volume>(<issue>10</issue>):<fpage>1649</fpage>–<lpage>1662</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.4074</pub-id><pub-id pub-id-type="pmid">25197816</pub-id></mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Figorilli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ferri</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zibetti</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Comparison between automatic and visual scorings of REM sleep without atonia for the diagnosis of REM sleep behavior disorder in Parkinson disease</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>(<issue>2</issue>):<fpage>zsw060</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsw060</pub-id></mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gong</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>CJ</given-names></string-name>, et al. <article-title>Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>6</issue>):<fpage>647</fpage>–<lpage>653</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2013.12.021</pub-id><pub-id pub-id-type="pmid">24841108</pub-id></mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dai</surname>
<given-names>YP</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Two polysomnographic features of REM sleep behavior disorder: clinical variations insight for Parkinson’s disease</article-title>. <source><italic toggle="yes">Parkinsonism Relat Disord</italic></source>. <year>2017</year>;<volume>44</volume>:<fpage>66</fpage>–<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.09.003</pub-id><pub-id pub-id-type="pmid">28923293</pub-id></mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Frauscher</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hogl</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Quantification of electromyographic activity during REM sleep in multiple muscles in REM sleep behavior disorder</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2008</year>;<volume>31</volume>(<issue>5</issue>):<fpage>724</fpage>–<lpage>731</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/31.5.724</pub-id><pub-id pub-id-type="pmid">18517042</pub-id></mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>SP</given-names></string-name>, et al. <article-title>Electromyography activity level in rapid eye movement sleep predicts neurodegenerative diseases in idiopathic rapid eye movement sleep behavior disorder: a 5-year longitudinal study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2019</year>;<volume>56</volume>:<fpage>128</fpage>–<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2019.01.018</pub-id><pub-id pub-id-type="pmid">30852128</pub-id></mixed-citation>
      </ref>
      <ref id="cit0046">
        <label>46.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Postuma</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Tuineaig</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2013</year>;<volume>36</volume>(<issue>11</issue>):<fpage>1579</fpage>–<lpage>1585</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.3102</pub-id><pub-id pub-id-type="pmid">24179289</pub-id></mixed-citation>
      </ref>
      <ref id="cit0047">
        <label>47.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ahmed</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Asi</surname>
<given-names>YT</given-names></string-name>, <string-name><surname>Sailer</surname>
<given-names>A</given-names></string-name>, et al. <article-title>The neuropathology, pathophysiology and genetics of multiple system atrophy</article-title>. <source><italic toggle="yes">Neuropathol Appl Neurobiol</italic></source>. <year>2012</year>;<volume>38</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2990.2011.01234.x</pub-id><pub-id pub-id-type="pmid">22074330</pub-id></mixed-citation>
      </ref>
      <ref id="cit0048">
        <label>48.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Koga</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Aoki</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Uitti</surname>
<given-names>RJ</given-names></string-name>, et al. <article-title>When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2015</year>;<volume>85</volume>(<issue>5</issue>):<fpage>404</fpage>–<lpage>412</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001807</pub-id><pub-id pub-id-type="pmid">26138942</pub-id></mixed-citation>
      </ref>
      <ref id="cit0049">
        <label>49.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Horsager</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Andersen</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2020</year>;<volume>143</volume>(<issue>10</issue>):<fpage>3077</fpage>–<lpage>3088</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa238</pub-id><pub-id pub-id-type="pmid">32830221</pub-id></mixed-citation>
      </ref>
      <ref id="cit0050">
        <label>50.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Borghammer</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Horsager</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Andersen</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Neuropathological evidence of body-first vs. brain-first Lewy body disease</article-title>. <source><italic toggle="yes">Neurobiol Dis</italic></source>. <year>2021</year>;<volume>161</volume>:<fpage>105557</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nbd.2021.105557</pub-id><pub-id pub-id-type="pmid">34763110</pub-id></mixed-citation>
      </ref>
      <ref id="cit0051">
        <label>51.</label>
        <mixed-citation publication-type="journal"><string-name><surname>McKeith</surname>
<given-names>IG</given-names></string-name>, <string-name><surname>Boeve</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Dickson</surname>
<given-names>DW</given-names></string-name>, et al. <article-title>Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2017</year>;<volume>89</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>100</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000004058</pub-id><pub-id pub-id-type="pmid">28592453</pub-id></mixed-citation>
      </ref>
      <ref id="cit0052">
        <label>52.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Eisensehr</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Linke</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Noachtar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Schwarz</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gildehaus</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Tatsch</surname>
<given-names>K</given-names></string-name>. <article-title>Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2000</year>;<volume>123</volume>(<issue>(Pt 6)(6)</issue>):<fpage>1155</fpage>–<lpage>1160</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/123.6.1155</pub-id><pub-id pub-id-type="pmid">10825354</pub-id></mixed-citation>
      </ref>
      <ref id="cit0053">
        <label>53.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Beach</surname>
<given-names>TG</given-names></string-name>, <string-name><surname>Adler</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Lue</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction</article-title>. <source><italic toggle="yes">Acta Neuropathol</italic></source>. <year>2009</year>;<volume>117</volume>(<issue>6</issue>):<fpage>613</fpage>–<lpage>634</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-009-0538-8</pub-id><pub-id pub-id-type="pmid">19399512</pub-id></mixed-citation>
      </ref>
      <ref id="cit0054">
        <label>54.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gagnon</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Bédard</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Fantini</surname>
<given-names>ML</given-names></string-name>, et al. <article-title>REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2002</year>;<volume>59</volume>(<issue>4</issue>):<fpage>585</fpage>–<lpage>589</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.59.4.585</pub-id><pub-id pub-id-type="pmid">12196654</pub-id></mixed-citation>
      </ref>
      <ref id="cit0055">
        <label>55.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>C</given-names></string-name>, <string-name><surname>P-P</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>K</given-names></string-name>. <article-title>Clinical variations in Parkinson’s disease patients with or without REM sleep behaviour disorder: a meta-analysis</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>40779</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep40779</pub-id><pub-id pub-id-type="pmid">28091622</pub-id></mixed-citation>
      </ref>
      <ref id="cit0056">
        <label>56.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chahine</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Kauta</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Daley</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Cantor</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Dahodwala</surname>
<given-names>N</given-names></string-name>. <article-title>Surface EMG activity during REM sleep in Parkinson’s disease correlates with disease severity</article-title>. <source><italic toggle="yes">Park Relat Disord</italic></source>. <year>2014</year>;<volume>20</volume>(<issue>7</issue>):<fpage>766</fpage>–<lpage>771</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.04.011</pub-id></mixed-citation>
      </ref>
      <ref id="cit0057">
        <label>57.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fernández-Arcos</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Serradell</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Diagnostic value of isolated mentalis versus mentalis plus upper limb electromyography in idiopathic REM sleep behavior disorder patients eventually developing a neurodegenerative syndrome</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>(<issue>4</issue>):<fpage>zsx025</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx025</pub-id></mixed-citation>
      </ref>
      <ref id="cit0058">
        <label>58.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Byun</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Sunwoo</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Kwon</surname>
<given-names>OY</given-names></string-name>, <string-name><surname>Jung</surname>
<given-names>KY</given-names></string-name>. <article-title>Comparison of rapid eye movement without atonia quantification methods to diagnose rapid eye movement sleep behavior disorder: a systematic review</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2022</year>;<volume>45</volume>(<issue>9</issue>):<fpage>zsac150</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsac150</pub-id><pub-id pub-id-type="pmid">35881545</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
